Replies to post #93962 on Biotech Values

[genisi]

Thanks for clarifying. I didn't think nerispirdine is different from Fampridine, but if SNY is already recruiting for P3 investigators perhaps it is.

[genisi]

Good news for ACOR:

Two projects in Phase II were discontinued. Data on Nerispirdine in improving the ability to walk in multiple sclerosis patients, and on SSR411298 in major depressive disorders, did not support progression to Phase III trials.

http://en.sanofi-aventis.com/binaries/20100429_q1_2010_en_tcm28-28188.pdf